The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study.
Gynecol Endocrinol
; 32(11): 886-890, 2016 Nov.
Article
em En
| MEDLINE
| ID: mdl-27223459
ABSTRACT
The efficacy of pathways inhibition and the combined effect of Everolimus (mTOR inhibitor) and Verapamil (CYP3A inhibitor) in ovarian hyperstimulation syndrome (OHSS) need to be tested. Therefore, the impact of a leucotriene receptor antagonist, an anticoagulant, a GnRH antagonist as well as Everolimus plus Verapamil (at various doses and days of administration) on an OHSS rat model was tested. Sixty three female Wistar rats were randomly divided into seven groups. The control group received saline, while the OHSS group received rec-FSH for four consecutive days. The other five groups received rec-FSH for four days and Montelukast daily, Heparin daily, GnRH antagonist daily, Everolimus plus Verapamil in the last two days (half days group) and Everolimus plus Verapamil (half dose group) daily, respectively. All groups received also hCG at the fifth day. Significantly reduced ovarian weight was observed in the Everolimus plus Verapamil groups (half days and half-dose groups) and the Montelukast group compared to the OHSS group (p = 0.001 and p = 0.001, respectively). The vascular permeability was significantly reduced in the Everolimus plus Verapamil group (half dose group) and the GnRH antagonist group compared to the OHSS group (p < 0.001 and p = 0.011, respectively). However, estradiol and progesterone levels did not differ significantly between the groups. Studying the inhibition of different pathways, we concluded that the co-administration of Everolimus and Verapamil (at half dose) is beneficial for reducing ovarian weight and vascular permeability in an OHSS animal model.
Palavras-chave
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tamanho do Órgão
/
Ovário
/
Permeabilidade Capilar
/
Verapamil
/
Síndrome de Hiperestimulação Ovariana
/
Inibidores de Proteínas Quinases
/
Serina-Treonina Quinases TOR
/
Inibidores do Citocromo P-450 CYP3A
/
Everolimo
Limite:
Animals
Idioma:
En
Revista:
Gynecol Endocrinol
Assunto da revista:
ENDOCRINOLOGIA
/
GINECOLOGIA
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Grécia